These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23064792)

  • 1. Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
    Zhang L; Han F; Zhang D; Dou XG
    Int J Mol Med; 2012 Dec; 30(6):1438-42. PubMed ID: 23064792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
    Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Viral Hepat; 2011 Apr; 18(4):280-6. PubMed ID: 20367792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
    Squadrito G; Raffa G; Restuccia T; Pollicino T; Brancatelli S; Raimondo G
    J Viral Hepat; 2002 Sep; 9(5):360-9. PubMed ID: 12225331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Kim SR; Ide YH; Sasase N; Imoto S; Deng L; Shoji I; Hotta H
    Intervirology; 2012; 55(1):1-11. PubMed ID: 21293098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
    Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
    J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
    Yen YH; Hung CH; Hu TH; Chen CH; Wu CM; Wang JH; Lu SN; Lee CM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):72-9. PubMed ID: 17973647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
    Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
    Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.